Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma Meeting Abstract
| Authors: | Vogl, D. T.; Younes, A.; Stewart, K.; Orford, K. W.; Bennett, M.; Siegel, D.; Berdeja, J. G. |
| Abstract Title: | Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma |
| Meeting Title: | 57th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 126 |
| Issue: | 23 |
| Meeting Dates: | 2015 Dec 5-8 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2015-12-03 |
| Language: | English |
| ACCESSION: | WOS:000368020103254 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V126.23.3059.3059 |
| Notes: | Meeting Abstract: 3059 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos |
